The history of humankind can be regarded from a medical point of view as a struggle against infectious diseases. Although infectious diseases were the leading cause of death worldwide at the beginning of the twentieth century, the introduction of sulfa drugs and penicillin into clinical use in the 1930s and 1940s respectively had a striking impact on the treatment of infectious diseases and decreased mortality dramatically. 1) After the clinical success of penicillin, intensive screening for antibacterial agents led to the discovery and successful clinical development of streptomycin, chloramphenicol, tetracycline, erythromycin, rifamycin, vancomycin, and cephalosporin between 1940 and 1960. ''The era of antibiotics'' led to optimism that infectious diseases can be controlled and prevented, and confidence that modern medicine would prevail against infectious diseases.
1) However, contrary to this optimism, infectious diseases are still the second-leading cause of death worldwide and the third-leading cause of death in developed countries. 2, 3) The global public health problem has been caused by emerging infections not yet recognized, re-emerging infections experienced previously that have reappeared in more virulent forms, and antimicrobial-resistant bacterial infections.
2) Antimicrobial resistance was recognized soon after the deployment of sulfonamides and penicillins, and it now appears that the emergence of antibiotic-resistant bacteria is inevitable to most every new drug. 1) To prevent the emergence and dissemination of resistant bacteria, continuing efforts to develop new antibacterial agents are needed. 4, 5) In this review, we focus on antibacterial agents, resistance to them, and their future development.
I. Definition of Antibiotics
Antibiotics, literally ''against life,'' are chemical compounds produced by actinomycetes, fungi, or bacteria that interfere with some essential bacterial structure or process with no effects on the eukaryotic host having the infectious agents. 6) Antibiotics exert two effects on bacteria: bacteriostatic and bactericidal. Bacteriostatic agents prevent the bacterial cells from growing, as exemplified by the drug chloramphenicol, and bactericidal agents kill bacteria, as exemplified by penicillin. 6) Although the term ''antibiotic'' was first introduced by Waksman in 1942 to denote chemical substances produced by a microorganism, semisynthetic modifications of natural products have produced a large variety of antibacterial agents, such as -lactam antibiotics and macrolides, that are also called antibiotics. 7) This definition distinguishes antibiotics from antibacterial agents totally synthesized by the chemist. At present, there are three classes of chemically synthesized antibacterial agents in clinical use: the sulfa drugs introduced in the 1930s, the quinolones introduced in the 1960s, and an oxazolidinone approved in the United States in 2000. 4, 7) These purely synthesized antibacterial agents are also treated as antibiotics in this review.
II. Targets of Antibiotics
Although a large number of antibiotics are used clinically, the variety of targets that they inhibit is limited. Antibiotics are usually classified on the basis of their chemical structure and mode of action. To understand how antibiotics work and why bacteria become resistance to them, a brief description of the targets of the main classes of antibiotics is required. The main classes of antibiotics inhibit four classical targets ( Fig. 1 ): (i) cell wall biosynthesis, (ii) protein biosynthesis, (iii) DNA and RNA biosynthesis, and (iv) folate biosynthesis. 8) 1. Inhibition of bacterial cell wall biosynthesis Since bacteria have high intracellular pressure, they must protect themselves from osmolysis with a rigid peptidoglycan, a meshwork of strands of glycan and peptide covalently crosslinked (Fig. 1) . Gram-negative bacteria, such as Escherichia coli and Pseudomonas aeruginosa, and Gram-positive bacteria, such as Staphylococcus aureus and Streptococcus pneumoniae, both have a peptidoglycan layer as part of their cell-wall structure. The peptidoglycan layer of Gram-positive bacteria is generally much thicker than that of Gramnegative bacteria, and constitutes the outermost layer.
9)
The peptidoglycan undergoes crosslinking of the glycan strands by the action of transglycosidase, and of the peptide strands by the action of transpeptidase.
6) Bifunctional enzymes possessing both transglycosidase and transpeptidase domains are the target sites of penicillins and cephaolosporins, collectively called -lactams.
10) -lactams attack and acylate the active site of the transpeptidase, leading to inactivation of the enzymes, hence they are called penicillin-binding proteins or PBPs. 10) In addition to -lactams, vancomycin, considered a last resort among antibiotics, also targets peptidoglycan to block cell-wall biosynthesis.
11) It binds to the D-Ala 4 -D-Ala 5 moiety of pentapeptides and thereby keeps the substrates away from transpeptidase and transglycosidase. 11) This substrate sequestration leads to the failure of peptidoglycan crosslinks, making the cell wall susceptible to osmolysis.
Inhibition of protein biosynthesis
Protein biosynthesis, a central reaction for cellular function, is catalyzed by ribosomes, composed of two nucleoprotein subunits, 30S and 50S subunits with about two-thirds RNA and one-thirds protein, in prokaryotes (Fig. 1) . 12) stantially from the eukaryotic counterpart, which explains the effectiveness and selective toxicity of many clinically important antibiotics. The X-ray structure of 30S and 50S subunits [12] [13] [14] and of 70S ribosome 15) reveals the architecture of this giant protein biosynthesis machinery in detail, and the peptidyltransferase activity deriving from the catalytic ribozyme domain of the 23S rRNA with no obvious assistance from protein subunits. 12) Due to the large number of steps involved in protein biosynthesis, initiation, elongation, and termination, it is not surprising that there are many steps to be blocked, or that many clinically useful antibiotics that interact with the conserved sequences of the 16S rRNA of the 30S subunit (aminoglycosides and tetracyclines) and the 23S rRNA of the 50S subunit (macrolides, chloramphenicol, lincosamides, and quinupristin-dalfopristin) have been found. [16] [17] [18] 3. Inhibition of DNA and RNA biosynthesis DNA replication is an essential process for all organisms. Bacterial chromosomal DNA is packed in a highly twisted (supercoiling) state in the cell, and dynamically changes its structure during the replication process. 19) The enzymes involved in interconversion of a topologically different form of the DNA are called topoisomerases. The DNA topoisomerases are classified into type I and type II. Type I topoisomerase transiently breaks either one strand at a time (also called a nick), while type II topoisomerase breaks both strands at the same time. 20) Due to the essential character of DNA replication, it is natural that microorganisms such as streptomycetes produce metabolites such as novobiocin and coumermycin that kill their neighbors by inhibiting the DNA replication process, the target of which has been found to be type II topoisomerase, specifically DNA gyrase. 20) Nalidixic acid, the prototype quinolone, was discovered to possess antibacterial activity in 1962 21) and was approved for urinary tract infections in 1964. 22) This finding led to more potent quinolone antibiotics, such as norfloxacin, ciprofloxacin, ofloxacin, and gatifloxacin, also called fluoroquinolone due to the presence of a fluorine substituent. These quinolones target the DNA gyrase and affect the double-strand cleavage/double-strand religation equilibrium in the gyrase catalytic reaction, in such a way that the cleaved complex accumulates by stabilization of the complex in the presence of quinolones. 20) A second type II topoisomerase, known as topoisomerase IV, is also implicated in DNA replication and decatenation of knotted daughter chromosomes at the end of bacterial DNA replication, 23) and thus is an important target, probably the primary one in Staphylococcus aureus. 24) Transcription is an essential process for decoding genetic information from DNA to RNA in all organisms. RNA polymerase of bacteria composed of different subunits with a stoichiometry of 2 0 ! to form the core enzyme catalyzes transcription. 25) Rifampicin (known in some countries as rifampin) is a semisynthetic version of rifamycin B, isolated from a strain of Amycolatopsis mediterranea (formerly known as Streptomyces mediterranea or Nocardia mediterranea). It is used principally in the treatment of tuberculosis and leprosy. 22) Rifampicin inhibits RNA polymerase by binding to the subunit of the enzyme at an allosteric site, not at the active site, as revealed by resistant mutations in clinical isolates of Mycobacterium tuberculosis and M. leprae 26) and X-ray structural analysis of the Thermus aquaticus core RNA polymerase complexed with rifampicin. 27) 4. Other targets Folic acid metabolism. The longest-used antibacterial agents are the sulfa drugs, or sulfonamides, first introduced in the 1930s. 6, 8) The current generation of sulfa drugs is sulfamethoxazole, which is used in combination with trimethoprim. 22) Each antibacterial agent is bacteriostatic when used individually, but they are bactericidal when used together. This effect makes the combination recipe remains clinically relevant in the treatment of many bacterial infections, such as urinary and respiratory tract infections. 22) Each of the drugs inhibits distinct steps in folic acid metabolism (Fig. 1) . Sulfamethoxazole inhibits dihydropteroate synthase in the biosynthetic pathway of folate in a competitive manner with higher affinity for the enzyme than a natural substrate, p-aminobenzoic acid.
22) The resulting dead-end product cannot be a substrate for the next enzyme, dihydrofolate synthase. Since humans do not have dihydropteroate synthase, sulfa drugs achieve high selectivity against bacteria. Trimethoprim inhibits dihydrofolate reductase, a key enzyme providing a onecarbon carrier, tetrahydrofolate, for the synthesis of deoxythymidylate, purine nucleotides, and the amino acids glycine and methionine. 28) In contrast to dihydropteroate synthase, dihydrofolate reductase is essential for all organisms. Trimethoprim is a competitive inhibitor of dihydrofolate reductase, and is 50,000 to 100,000 times more active against bacterial enzymes than against the human counterparts, achieving high selectivity. 22) A combination of trimethoprim and sulfa drugs acting at distinct steps on the same biosynthetic pathway shows synergy and a reduced mutation rate for resistance as compared to the use of each drug alone, providing validation of combination chemotherapy.
Cell membranes. The integrity of cell membranes, including the outer membrane of Gram-negative bacteria, is essential to all organisms. Cationic peptides exemplified by the polymyxins, a group of cyclic peptides with a fatty acid chain attached to the peptide, attack the cytoplasmic membrane of Gram-positive and Gram-negative bacteria, and the outer membrane of Gram-negative bacteria.
29) The interaction of the cationic peptide and the membrane disrupts membrane organization and causes increased permeability of cell components, which eventually leads to cell-killing. 29) The toxicity of polymyxin B due to its membrane-active nature restricts its use in topical applications. 29) A second set of antibacterial peptides is bacteriocins produced by both Gram-positive and Gram-negative bacteria to compete with neighboring bacterial cells. 30) With some exceptions, most of these bacteriocins, such as nisin, permeabilize target cell membranes. 29, 30) Studies on the mechanism of action of nisin show that it binds with high affinity to a docking molecule, lipid II, a precursor of cell-wall biosynthesis, leading to the hypothesis of the dual functionality of nisin. 31, 32) Recent structural analysis of the nisin-lipid II complex reveals that a novel lipid II recognition motif of nisin and related lantibiotics (lanthionine-containing antibiotic peptides) binds to the pyrophosphate moiety of lipid II. This provides a basis for rational design of future antibiotics.
33)

III. Resistance to Antibiotics
Since sulfonamide and penicillin were introduced into clinical use in the 1930s and 1940s respectively, people were captured by the illusion that infectious diseases were totally controlled by antibiotics. The widespread use of antibiotics, however, imposes strong selection pressure for the development of antibiotic resistance, a presentday major public health problem. 4, 34) We must now accept that the occurrence of antibiotic resistance is inevitable, that is, it is only a question of time. 35) As the frequency of antibiotic use increases, the speed of resistance development also increases, thereby reducing the effectiveness of the antibiotics. Clinically significant resistance appears after months to years whenever a new antibiotic is introduced into medical use. 36, 37) For example, penicillin resistance was detected a few years after its clinical debut in 1942, 38) and streptomycin, a year after its discovery in 1944. 35, 39) In the exceptional case of vancomycin, its resistance appeared almost 30 years (in 1987) after its clinical introduction. 40) The long delay was likely due in part to limited use of vancomycin in the first 25 years, since other effective antibiotics were available during the ''antibiotic era'' of the 1950s through the 1960s. But then indiscriminate use of antibiotics resulted in the emergence of methicillin-resistant Straphylococcus aureus (MRSA), which exhibits multiantibiotic resistance against many structurally unrelated antibiotics. 41) In turn, vancomycinresistant Enterococci (VRE) appeared in 1986 due to widespread use of vancomycin, which was regarded as the antibiotic of last resort. 11, 42) Then the discovery of partially vancomycin-resistant strains of S. aureus in 1997 lead to the first case of fully vancomycin-resisitant S. aureus. 43) More to the point, what makes the problem more complicated is that about 50% of antibiotics are used for prophylaxis, chemotherapy, and growth promotion in animals. 42, [44] [45] [46] There is now evidence that antibiotic use in animals plays a role in the development of antibiotic-resistance in human pathogens. 47) A case of causal relationship of the glycopeptides, vancomycin and avoparicin, pushed the European Union to ban the use of avoparcin in 1997 for growth promotion on the basis of the ''Precautionary Principle.'' 48) To combat these life-threatening problems, continuing efforts to develop new antibiotics are obviously needed. Since the introduction of nalidixic acid in 1962, a totally new class of antibiotic oxazolidinones (linezolid) and cyclic lipopeptides (daptomycin) were approved in 2000 and 2003 respectively for clinical use in the United States. 4, 8) Although these new antibiotics are effective against vancomycin-resistant MRSA and Enterococci, it is clear that the problematic pathogens will eventually develop resistance to these compounds too, and that the therapeutic lifetime of the new antibiotics will be shortened if we use them indiscriminately. Indeed, clinical isolates of S. aureus and Enterococcus faecium showing linezolid resistance were first reported in 2001, a year after launch. 49, 50) Antibiotic resistance can be either intrinsic (natural) or acquired. An example of intrinsic resistance is Pseudomonas aeruginosa, whose low membrane permeability is likely to be a main reason for its innate resistance to many antibiotics. 9, 51) Acquired resistance is caused by acquisition of a plasmid and/or transposon that harbors determinants for resistance, or by chromosome mutation. 35, 42) The major mechanisms of antibiotic resistance are (i) prevention of accumulation of antibiotics either by decreasing uptake or increasing efflux, (ii) inactivation of antibiotics either by hydrolysis or by modification, and (iii) qualitative alteration of the target that reduces the affinity for antibiotics either by mutation or by target modification, or quantitatively by overproduction of the target (Fig. 2) . A, Prevention of accumulation of antibiotics by decreasing uptake or increasing efflux. B, Inactivation of antibiotics by hydrolysis or modification, in this case, phosphorylation. C, Alteration of targets qualitatively to reduce the affinity for antibiotics or quantitatively by overproduction of the target.
Efflux pumps
Prevention of antibiotic access to their targets results from either decreasing the influx or increasing the efflux of antibiotics across biological membranes (Fig. 2) . 9, 52) Pseudomonas aeruginosa, an opportunistic pathogen, exemplifies this mechanism of antibiotic resistance. Mutants lacking an outer membrane porin channel, OprD2, decrease the uptake of carbapenem, a -lactam antibiotic, and increase resistance to this antibiotic due to low accessibility of the drug to its target, penicillinbinding protein. 9, 53) A mutation resulting in overexpression of a multidrug efflux pump, MexAB-OprM, renders this organism resistant to a wide variety of structurally unrelated antibiotics. 54, 55) Since a loss-of-function mutation in the MexAB-OprM efflux pump causes hypersensitivity toward various antibiotics, the intrinsic resistance of this organism appears to be due mainly to an active efflux of antibiotics. 54, 56) From the first indication that plasmid-coded tetracycline resistance in E. coli is due to energy-dependent efflux of the drug, 52) this mechanism of antibiotic resistance, namely transmembrane efflux of antibiotics, attracted scientists' attention, and led to the recognition of the widespread presence of multidrug efflux pumps in bacteria that create resistance to clinically important drugs. 9, 51) The efflux pumps are grouped into five families based on their mechanisms and primary sequence homologies: (i) the major facilitator superfamily (MFS), (ii) the resistance-nodulation-division (RND) family, (iii) the small multidrug resistance (SMR) family, (iv) the multidrug and toxic compounds extrusion (MATE) family, and (v) the ATP-binding cassette (ABC) superfamily. 57) Each member of the first four groups is a secondary transporter that uses proton motive force (or sodium ion motive force for the MATE family) to expel antibiotics from cells. 57) Members of the ABC superfamily are primary transporters that use energy liberated by ATP hydrolysis such as LmrA of Lactococcus lactis.
58)
The ubiquitous multidrug efflux pumps raised the question how they recognize and transport multiple structurally unrelated antibiotics, and the question what their natural physiological role is. Recently, there has been tremendous progress in structural analysis of multidrug efflux pumps and their cognate regulators that has provided significant insight into these questions. 57, 59) Efflux pumps of the RND family are composed of an inner membrane proton antiporter, a periplasmic membrane fusion protein, and an outer membrane exit channel. 9, 51, 57) The crystal structures of an inner membrane component, AcrB of E. coli (Fig. 3A) , 60) a periplasmic protein, MexA of P. aeruginosa (Fig. 3B) , 61, 62) and outer membrane channels, TolC of E. coli 63) and OprM of P. aeruginosa (Fig. 3B ), 64) have been solved. It has been suggested that the functional tripartite efflux pump of P. aeruginosa comprises MexB trimer, a homolog of AcrB, OprM trimer, and three to nine protomers of MexA. Hence the stoichiometry of the pump is predicted to be 1:1:1, 1:1:2, or 1:1:3 for MexB:OprM:MexA. 61, 62, 65) Quantitative analysis of each subunit in intact cells supports the 3-fold MexA-dimer model in which the functional pump is composed of MexB trimer, OprM trimer, and three dimers of MexA (Fig. 3B) . 61, 66) The mechanism of multidrug efflux by the tripartite pump has been suggested by the striking features of the AcrB structure. 60) Substrates are collected from the inner and outer leaflet of the plasma membrane through vestibules, which are formed between AcrB protomers, captured on the wall of the central cavity, and then actively transported through the pore into the TolC channel (Fig. 3A) . 60, 67, 68) The wide substrate specificity of the multidrug efflux pump can be explained by the large central cavity that interacts with different substrates, mainly through hydrophobic interaction, as well as electrostatic interaction. 69) 2. Inactivation of antibiotics Enzymatic inactivation of antibiotics either by hydrolysis or by modification is a major mechanism of resistance in pathogenic bacteria to natural antibiotics such as -lactams (penicillins and cephalosporins), aminoglycosides, and chloramphenicol. 35, 36) The classic case is the hydrolysis of the four-membered -lactam ring in penicillins and cephalosporins by hydrolytic enzymes, -lactamases, resulting in products that cannot inhibit their targets, penicillin binding proteins (PBPs) (Fig. 4A) . 35, 36) A group of -lactamases, which have serine residue at their active sites, form penicilloyl-OSer -lactamase covalent intermediates as in the catalytic cycle of PBPs, which also form penicilloyl-O-Ser PBPs.
70) The different lifetimes of each penicilloyl-O-Ser enzyme intermediate result in totally different outcomes (Fig. 4A) . The long lifetime of penicilloyl-O-Ser PBPs results in inactivation of PBP transpeptidase activity, leading to prevention of cross-linking. 70, 71) By contrast, the deacylation rate of penicilloyl-O-Serlactamase is fast, resulting in hydrolyzed, ring-opened penicilloic acid that is deactivated and nonfunctional as a PBP pseudosubstrate.
36) The structural and mechanical similarities of the serine -lactamases to the PBPs suggest evolution of the -lactamase from PBPs. 71, 72) In contrast to -lactams, the aminoglycoside antibiotics do not possess hydrolytically fragile groups. Thus, the enzymatic inactivation strategy for aminoglycoside-resistant bacteria is covalently to modify the OH and NH 2 groups of the aminoglycosides (Fig. 4B) . 73, 74) There are three types of aminoglycoside-modifying enzymes: aminoglycoside acetyltransferases, which transfer the acetyl group from acetyl CoA, aminoglycoside phosphotransferases, which transfer the phosphoryl group from ATP, and aminoglycoside adenylyltransferases, which transfer the AMP group from ATP. 73, 74) Aminoglycosides bind specifically to regions near the A site for aminoacyl-tRNA binding of 16S rRNA on the 30S ribosome subunit by hydrogen bond network through the various hydroxyl and amino substitutions of the antibiotics. 16, 17) This high affinity binding of aminoglycosides with rRNA inhibits protein biosynthesis. 16, 17) Enzymatic modification of aminoglycosides disrupts the hydrogen bond network, resulting in the considerably lower affinity of the drugs for the rRNA.
Chloramphenicol has been found to inhibit protein biosynthesis by preventing binding of tRNA to the A site of the ribosome. 75, 76) Recent structural analysis of the bacterial 50S ribosome subunit complexed with chloramphenicol has revealed that the antibiotic interacts specifically with various nucleotides of the peptidyl transferase cavity of the 23S rRNA through hydrogen bonds without any interactions with ribosomal proteins. 18) Chloramphenicol acetyltransferases, widely distributed among bacterial pathogens of all genera, inactivate chloramphenicol by transferring the acetyl group from acetyl CoA (Fig. 4C) . 77) This modification of chloramphenicol again results in the considerably lower affinity of the antibiotic for the rRNA.
Enzymatic inactivation of antibiotics is one of the most common mechanisms of antibiotic resistance. 35) The antibiotic-resistant clinical isolates in most cases inherit the antibiotic-resistance genes on R (resistance) plasmids. 35) Although definitive evidence for the origin of the antibiotic-resistant determinants remains to be found, such resistance determinants most probably are acquired by pathogenic bacteria from a pool of resistance genes in other microbial genera, including antibiotic-producing organisms. 35 ) -lactamase was identified in 1940, several years before the introduction of penicillin into clinical use, indicating that there has been a pool of antibiotic resistant genes in nature. 78) 
Alteration of the target
In contrast to enzymatic inactivation of natural antibiotics, no enzymes that hydrolyze or modify manmade antibiotics such as sulfonamides, trimethoprim, and quinolones have been found. 26) The mechanism of antibiotic resistance for these synthetic antibiotics and those natural products such as rifampicin, where inactivating enzymes have not been found, is commonly achieved by target alterations. 26) The most common mechanism of target alteration is the acquisition of new genes, carried on plasmids or transposons, that result in enzymatic modification of the normal target so that it does not bind the antibiotics. The erythromycin family of macrolides and the streptogramin B family exemplify this mechanism of antibiotic resistance. 36, 79) In erythromycin-resistant bacteria, the exocyclic amino group of a specific adenine residue, A2058, in 23S rRNA is mono-or dimethylated by an Erm (erythromycin ribosome methylation) methyltransferase, resulting in cross-resistance to macrolides, lincosamides, and streptogramin B (MLS B phenotype) (Fig. 5A) . 80, 81) This modification reduces the affinity of the rRNA for the antibiotics but does not interfere with protein biosynthesis. The recent crystal structure of the 50S subunit of the ribosome complexed with erythromycin revealed the importance of hydrogen bonds between erythromycin and A2058 of 23S rRNA. 18) Erm is the major resistance mechanism in antibioticresistant Staphylococcus aureus and is present in erythomycin-producing organisms as a self-protection mechanism. 79, 80) (Fig. 5B) . 84) On the other hand, VanC and VanE replace the terminal DAla with D-Ser, leading to low-level resistance. 85) -lactam antibiotic resistance can be caused not only by -lactamase, but also by alteration (or mutation) of PBPs that have low affinity for the -lactams, as well as by acquisition of new PBPs with low affinity for the antibiotic. 26, 36) Unlike many other pathogens, Streptococcus pneumoniae does not employ -lactamases as the major mechanism of resistance to -lactams. Its resistance to -lactams is due to alteration of PBPs.
26) The most highly -lactam-resistant clinical isolates produce altered forms of high-molecular weight (Mr) PBPs (1A, 1B, 2A, 2B, and 2X) that have reduced affinity forlactams. [86] [87] [88] [89] It is now known that low-affinity forms of high-Mr pneumococcal PBPs have arisen by interspecies homologous recombination, 26, 90, 91) suggesting the occurrence of gene shuffling in nature. MRSA acquires the mecA gene, which encodes a new PBP, termed PBP2 0 (also PBP2A), with low affinity for all -lactams. 26, 36) Although the source of the PBP2 0 gene is not known, horizontal transmission of the mecA gene from other Staphylococcus species has been postulated. 26, [92] [93] [94] 
IV. New Approaches to Development of Novel Antibiotics
There is a pressing need for new antibiotics due to the inevitable development of resistance that follows the introduction of antibiotics to the clinic. In the past 10-15 years, there has been a dramatic increase in the emergence of antibiotic-resistant bacteria, including multiantibiotic resistant strains in both community and hospital settings. 95, 96) The main strategy of the pharmaceutical industry for development of new therapeutics has been modification of existing antibiotics, such as the second-and third-generation molecules of the bestselling antibiotic groups of -lactams, macrolides, and fluoroquinolones. 8) Although this approach is effective, it has turned out to be increasingly difficult to launch new drugs to meet the needs of the community. Almost 40 years were required for the development of a new structural class of synthetic antibiotics of broad spectrum, the oxazolidinone linezolid, since the introduction of nalidixic acid in 1962. 8) Since the main classes of antibiotic targets are cell wall, protein, DNA/ RNA, and folate biosynthetic pathways, expanding the number of potential targets is of great importance for discovery and development of new antibiotics to keep pace with the emergence of antibiotic resistance.
The explosion in microbial genome sequencing in the past decade has revealed over 200 complete bacterial genome sequences, including important pathogens (270 as of January 8, 2006 ; http://gib.genes.nig.ac.jp/), which provides more opportunities to identify and validate new antibacterial targets. 8, 96) The bioinformatics approach is based on searches of open reading frames (ORFs) conserved among potential pathogenic bacteria, as well as ORFs found only in prokaryotes, not in eukaryotes. 8, 96) An example of this approach compared the 4,289 E. coli genes against the genomes of Haemophilus influenzae, Mycoplasma, S. pneumoniae, Streptococci, Chlamydia pneumoniae, Klebsiella, and P. aeruginosa. The process identified 246 conserved genes in all these bacteria, of which 68 genes are not found in humans. 97) Next, loss-of-function tests showed that 18 genes were essential, 16 genes nonessential, and 34 genes unknown as to function. In this bioinformatic analysis, three genes were finally chosen as targets for new respiratory-tract antibiotics. 97) The key aspect of the potential targets is that they are essential for bacterial growth or viability and are expressed under the conditions of the infection process. 96, 98) There is now good evidence to suggest that the expression pattern of pathogens during infection can be quite different from that in culture medium. 3, 96, 99) In fact, traditional whole-cell screenings focus on targets that are important for in vitro growth in rich media and thus might not identify inhibitors of target systems that are induced specifically in vivo and are relevant to the infection process.
Several new techniques detect and monitor gene expression during infection. In vivo expression technology (IVET) allows identification of genes specifically induced in the host. It has been applied successfully to several pathogens. 100, 101) A similar technique, differential fluorescence induction (DFI), utilizes promoter fusions with green fluorescent protein to identify active promoters in vivo. 101, 102) Signature-tagged mutagenesis (STM) is another technique that identifies the genes required for the infection process and viability in vivo. 101, 103) Combinatorial chemistry has a significant impact on the discovery of new antibiotics. 104) This new approach to high-throughput screening requires large, diverse synthetic compounds and natural products. In nature, biosynthetic assembly lines of polyketides and nonribosomal peptides furnish an example of combinatorial libraries.
104) The structures of complex polyketide natural products, such as erythromycin, are assembled by multifunctional polyketide synthases (PKSs) that contain modular arrangements of functional domains. 104) A library of >50 macrolides that are not produced by chemical methods have been generated by simultaneous manipulation of multiple catalytic centers of erythromycin PKS genes.
105)
The high-resolution X-ray crystal structures of the 30S and 50S ribosomal subunits as well as whole 70S ribosome complexed with antibiotics offer a good opportunity to develop new antibiotic compounds. [16] [17] [18] 106, 107) As to macrolides, the 3D structures of the ligands adjacent to peptidyl-transferase center on the 50S ribosomal subunit reveal how an inhibitor binds to the target, thus facilitating computational analysis of other factors that contribute to binding, such as shape and electrostatic complementlity. 18, [106] [107] [108] This structure-based drug-design approach produces promising potential macrolide derivatives against respiratory tract pathogens resistant to macrolides and ketolides, penicillin, chloramphenicol, and sulphamethoxazole.
106)
V. New Targets
Historically, the main classes of antibiotics inhibit four classical targets: (i) cell wall biosynthesis, (ii) protein biosynthesis, (iii) DNA and RNA biosynthesis, and (iv) folate coenzyme biosynthesis.
8) The recent advance in bacterial genomics has changed the antibacterial therapeutic environment from target-poor to target-rich. The genomics provide many molecular targets to be identified and effectively screened: 5, 96) peptide deformylase (PDF), 109) aminoacyl-tRNA synthetase, 110) fatty acid biosynthesis, 111) isoprenoid biosynthesis, 112) lipid A biosynthesis, 113) efflux pump, 114) aromatic amino acid biosynthesis, 96) DNA replication (GyrB subunit inhibitor), 115) protein secretion, 116) cell wall biosynthesis (sortase), 117) proteasome, 118) glyoxylate cycle, 119) and signal networks (two-component systems and quorum sensing pathways). 120, 121) 1. Peptide deformylase (PDF) Although there have been few novel antibacterial lead compounds that produce commercially successful antibiotics from these new approaches so far, PDF appears to have gained intense awareness recently as a promising target. 109) Although the bacterial protein-synthesizing machinery is similar to those of mammalian cells, there are sufficient differences to allow selective inhibition of this process in bacteria. One significant difference is the transformylation and subsequent deformylation of initiating methionine in bacteria. 122, 123) Unlike cytosolic protein synthesis in mammalian cells, protein synthesis in bacteria and mitochondria is initiated with N-formylmethionine, 124, 125) which is formed by N-methionyl-tRNA transformylase. 126) In bacteria, but not in mitochondria, the N-formylmethionine of newly synthesized protein is removed sequen-tially by PDF and a methionine amino peptidase to produce mature proteins. 125, 127) This essential role of bacterial PDF in protein biosynthesis provides a rational basis for selective inhibition. PDF inhibitor-resistant mutants appear easily like other antibiotics; the transformylase gene has changed in E. coli, H. influenzae, and S. aureus. [128] [129] [130] But resistant mutants defective in the transformylase gene have a slow growth phenotype, 109, 128) suggesting diminished virulence of the pathogenic bacteria. Indeed, a PDF inhibitor-resistant mutant of S. aureus showed weakened virulence in a murine thigh-abscess model, 130) and hence this type of resistance might not emerge in a clinical situation. 109) 2. Non-mevalonate pathway Although the mevalonate pathway has been known for several decades as the source of isoprenoids, an alternative non-mevalonate pathway has recently been found, 112, 131) in which the first intermediate 1-deoxy-Dxylulose 5-phosphate, also an intermediate in thiamine and pyridoxal biosynthesis, is formed by condensing glyceraldehyde 3-phosphate and pyruvate. 112) In contrast to animals that use the mevalonate pathway exclusively, many bacteria, including clinically important pathogens, utilize the non-mevalonate pathway. 112) Since isoprenoid biosynthesis is essential and humans do not have enzymes of the non-mevalonate pathway, all of the seven enzymes in the non-mevalonate pathway are attractive antibacterial targets for the development of novel antibiotics. In fact, the 2C-methyl-D-erythritol 4-phosphate synthase inhibitor fosmidomycin has been shown to possess antibacterial activity. 132) On the other hand, bacterial bioinformatics suggests that genes encoding the mevalonate pathway are essential in S. aureus and other Gram-positive cocci. Hence inhibitors of the mevalonate pathway should work against these Gram-positive pathogens. 133, 134) 3. Bacterial fatty acid synthesis Fatty acid biosynthesis is essential for bacterial growth. 5, 96) In mammals, fatty acid is synthesized by a single large polypeptide called fatty acid synthase (FAS), 135) whereas in the bacterial FAS system individual enzymes perform the individual synthetic steps, 136) suggesting that the differences in the systems are the basis for selective inhibition by natural products, such as cerulenin, thiolactomycin, and isoniazid. 5) Recently, an antibacterial antiseptic, triclosan, was shown to inhibit enoyl-ACP reductase (FabI) in E. coli, 137) and isoniazid, an important antituberculosis drug, was found to be activated by mycobacterial KatG catalase to acylate NAD bound in the active site of InhA, the homolog of FabI of E. coli, and thus to inhibit the enzyme. 138) Thus the fatty acid biosynthetic pathway is validated to provide good targets. Screening against FabI has identified two novel antibacterial leads (benzodiazepine and imidazole compounds) that inhibit S. aureus enzyme selectively, but not the human FAS system. 111) Recent structural analysis of bacterial fatty acid biosynthetic enzymes complexed with ligand is also facilitating the lead optimization process. [139] [140] [141] 
Bacterial virulence factors
In the past decades, antibiotic discovery programs have focused on eliminating infection by bactericidal and/or bacteriostatic agents that target essential processes for bacterial viability in vitro. However, pathogenic bacteria elaborate virulence factors, involved in adhesion, invasion, and host defense system evasion, to establish an infection 142) the expression of which is carefully regulated in response to environmental changes. 99) Recently developed techniques, such as IVET, DFI, and STM, have identified genes that are involved in the infectious process of pathogenic bacteria in the context of their expression. [100] [101] [102] [103] According to ''Koch's molecular postulates,'' genetic disruption of an essential virulence factor should reduce bacterial virulence. 143) In fact, allelic replacement of individual genes causes attenuation of virulence in in vivo models, confirming their product's role in infection. 99) They are global regulators of virulence factor expression and sortase in S. aureus, 117, 144) the two-component system in S. pneumoniae 145) and in S. aureus, 146) the quorum sensing system in P. aeruginosa, 147) host cell invasion in S. enterica, 148) S. flexneri, 149) and L. monocytogenes, 150) and the glyoxylate cycle in M. tuberculosis.
119) These factors are unique to bacteria, and hence the virulence factors can be a target for development of new antibiotics. 99) The current concept of antibiotic discovery is that broad-spectrum agents are preferred over narrow-spectrum ones, implying that targets should be conserved among pathogenic bacteria. 99) In this context, inhibitors targeting these virulence factor-related targets are narrow-spectrum. Among them, sortase, which covalently attaches cell-surface proteins to the peptidoglycan layer in Gram-positive bacteria, is an attractive drug target, since sortase has a common substrate specificity (LPXTG) [151] [152] [153] and should be easily accessible to drugs due to its cell-surface location. In addition, the 3D structure of sortase has been determined by NMR spectroscopy, enabling rational structure-based drug design. 154) Thus there is an increasing possibility of a single sortase inhibitor with activity against many Grampositive pathogens. 99) 
VI. Conclusion
The development of antibiotics is among the greatest achievements of medicine in human history, but it is clear that infectious diseases are still of major medical and scientific concern. 96, 98) The ability of bacterial pathogens to gain resistance to new antibiotics has been proved since the early introduction of sulfonamides and penicillins into clinical use. 8, 35) To keep pace with the development of antibiotic resistance in bacterial patho-gens, we must continue the development of novel antibiotics. 4, 8, 155) In addition, it is of great importance to rethink strategies for preserving and extending the useful life of antibiotics, such as rotating the use of antibiotics 156) and combination antibiotic therapy. 8, 36) The challenges can be met only by understanding the fundamental biology of bacterial pathogens and hostpathogen interactions, and by valuing the antibiotics as precious, finite resources. 36) 
